We are live on ! Find out more
T. Rowe Price Associates

T. Rowe Price Associates Portfolio holdings

AUM $865B
1-Year Est. Return 30.76%
 

T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.

This Fund
S&P 500
This Quarter Est. Return
-16.43%
1 Year Est. Return
+30.76%
3 Year Est. Return
+117.39%
5 Year Est. Return
+143.85%
10 Year Est. Return
+1,089.89%
AUM
$791B
AUM Growth
-$200B
Cap. Flow
-$11.4B
Cap. Flow %
-1.44%
Top 10 Hldgs %
26.42%
Holding
3,063
New
88
Increased
1,490
Reduced
1,207
Closed
101

Top Buys

Rank Stock Value
1
BDX icon
Becton Dickinson
BDX
+$3.46B
2
UNH icon
UnitedHealth
UNH
+$2.79B
3
CRM icon
Salesforce
CRM
+$2.38B
4
SHW icon
Sherwin-Williams
SHW
+$1.41B
5
PM icon
Philip Morris
PM
+$1.34B

Sector Composition

Rank Sector Weight
1 Technology 26.68%
2 Healthcare 19.49%
3 Consumer Discretionary 13.07%
4 Financials 11.17%
5 Communication Services 8.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
EGIO
2901
DELISTED
Edgio, Inc. Common Stock
EGIO
$29K ﹤0.01%
313
+32
+11% +$4.61K
LAB icon
2902
Standard BioTools
LAB
$312M
$28K ﹤0.01%
17,700
-6,961
-28% -$17.2K
BRDS
2903
DELISTED
Bird Global, Inc.
BRDS
$28K ﹤0.01%
2,575
+1,979
+332% +$60.3K
ABUS icon
2904
Arbutus Biopharma
ABUS
$907M
$27K ﹤0.01%
+10,083
New +$25.8K
CENN icon
2905
Cenntro
CENN
$8.53M
$27K ﹤0.01%
+29
New +$30.7K
PLSE icon
2906
Pulse Biosciences
PLSE
$3.09B
$27K ﹤0.01%
17,600
+2,955
+20% +$7.43K
MTEM
2907
DELISTED
Molecular Templates, Inc.
MTEM
$26K ﹤0.01%
1,905
-239
-11% -$5.59K
FPAY
2908
DELISTED
FlexShopper
FPAY
$25K ﹤0.01%
27,700
ATHX
2909
DELISTED
Athersys, Inc. Common Stock
ATHX
$25K ﹤0.01%
3,876
-720
-16% -$7.97K
KPRX icon
2910
Kiora Pharmaceuticals
KPRX
$11.7M
$24K ﹤0.01%
143
BBIG
2911
DELISTED
Vinco Ventures, Inc. Common Stock
BBIG
$24K ﹤0.01%
+876
New +$29.4K
RMTI icon
2912
Rockwell Medical
RMTI
$29.6M
$23K ﹤0.01%
1,746
RIDE
2913
DELISTED
Lordstown Motors Corp. Class A Common Stock
RIDE
$23K ﹤0.01%
989
+60
+6% +$1.93K
CTXR icon
2914
Citius Pharmaceuticals
CTXR
$21M
$21K ﹤0.01%
896
+60
+7% +$1.65K
NGNE icon
2915
Neurogene
NGNE
$738M
$21K ﹤0.01%
1,015
-157
-13% -$3.83K
ZYNE
2916
DELISTED
Zynerba Pharmaceuticals, Inc
ZYNE
$21K ﹤0.01%
18,200
ALR
2917
DELISTED
AlerisLife Inc
ALR
$21K ﹤0.01%
17,400
STEX
2918
Streamex Corp
STEX
$87.3M
$20K ﹤0.01%
3,020
OUST icon
2919
Ouster
OUST
$3.33B
$20K ﹤0.01%
1,243
+99
+9% +$2.78K
URG
2920
Ur-Energy
URG
$537M
$20K ﹤0.01%
18,764
+2,279
+14% +$3.04K
LPTH icon
2921
Lightpath Technologies
LPTH
$862M
$19K ﹤0.01%
15,300
MKFG
2922
DELISTED
Markforged Holding Corporation
MKFG
$19K ﹤0.01%
+1,051
New +$30.7K
EMAN
2923
DELISTED
eMagin Corporation
EMAN
$18K ﹤0.01%
27,300
ML
2924
DELISTED
MoneyLion Inc.
ML
$18K ﹤0.01%
+460
New +$24.4K
AKBA icon
2925
Akebia Therapeutics
AKBA
$248M
$17K ﹤0.01%
47,100
-15,507
-25% -$6.51K

Similar funds

T. Rowe Price Associates's Q2 2022 Portfolio in Review

As of Q2 2022, T. Rowe Price Associates held 3,063 positions worth $791B, down 20% from $992B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

T. Rowe Price Associates's Q2 2022 filing shows 88 new, 1,490 increased, 1,207 reduced and 101 closed positions. Its largest new stake was ESAB: 6,073,363 shares worth $266M. The largest sale was Meta Platforms (Facebook), an estimated $4.44B.

By sector, the portfolio is most concentrated in Technology at 27% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.

  • T. Rowe Price Associates's largest Q2 2022 buy was ESAB: 6,073,363 shares worth $266M.
  • T. Rowe Price Associates added most to Becton Dickinson in Q2 2022, an estimated $3.46B increase.
  • T. Rowe Price Associates's biggest Q2 2022 reduction was Meta Platforms (Facebook), cutting an estimated $4.44B.
  • T. Rowe Price Associates fully exited Ortho Clinical Diagnostics Holdings plc Ordinary Shares in Q2 2022, selling an estimated $364M.
  • T. Rowe Price Associates's ten largest holdings make up 26% of its $791B portfolio in Q2 2022.
  • T. Rowe Price Associates opened 88 new positions and closed 101 in Q2 2022.
  • T. Rowe Price Associates's portfolio value fell 20% quarter-over-quarter to $791B.

Based on T. Rowe Price Associates's 13F filing for Q2 2022, filed 15 Aug 2022.